173 related articles for article (PubMed ID: 34800542)
1. PLEKHA7 signaling is necessary for the growth of mutant KRAS driven colorectal cancer.
Jeung HC; Puentes R; Aleshin A; Indarte M; Correa RG; Bankston LA; Layng FIAL; Ahmed Z; Wistuba I; Yao Y; Duenas DG; Zhang S; Meuillet EJ; Marassi F; Liddington RC; Kirkpatrick L; Powis G
Exp Cell Res; 2021 Dec; 409(2):112930. PubMed ID: 34800542
[TBL] [Abstract][Full Text] [Related]
2. An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors.
Indarte M; Puentes R; Maruggi M; Ihle NT; Grandjean G; Scott M; Ahmed Z; Meuillet EJ; Zang S; Lemos R; Du-Cuny L; Layng FIAL; Correa RG; Bankston LA; Liddington RC; Kirkpatrick L; Powis G
Cancer Res; 2019 Jun; 79(12):3100-3111. PubMed ID: 31040156
[TBL] [Abstract][Full Text] [Related]
3. Dual inhibition of VEGF and PARP suppresses KRAS-mutant colorectal cancer.
Zhong L; Wang R; Wang Y; Peng S; Ma Y; Ding S; Yang H; Chen S; Luo X; Wang W
Neoplasia; 2020 Sep; 22(9):365-375. PubMed ID: 32629177
[TBL] [Abstract][Full Text] [Related]
4. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
5. Riok1, A Novel Potential Target in MSI-High p53 Mutant Colorectal Cancer Cells.
Shechter S; Ya'ar Bar S; Khattib H; Gage MJ; Avni D
Molecules; 2023 May; 28(11):. PubMed ID: 37298928
[TBL] [Abstract][Full Text] [Related]
6. Mutant KRAS promotes liver metastasis of colorectal cancer, in part, by upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway.
Chu PC; Lin PC; Wu HY; Lin KT; Wu C; Bekaii-Saab T; Lin YJ; Lee CT; Lee JC; Chen CS
Oncogene; 2018 Jun; 37(25):3440-3455. PubMed ID: 29559746
[TBL] [Abstract][Full Text] [Related]
7. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
Wong CC; Qian Y; Li X; Xu J; Kang W; Tong JH; To KF; Jin Y; Li W; Chen H; Go MY; Wu JL; Cheng KW; Ng SS; Sung JJ; Cai Z; Yu J
Gastroenterology; 2016 Nov; 151(5):945-960.e6. PubMed ID: 27451147
[TBL] [Abstract][Full Text] [Related]
8. BMP4 and PHLDA1 are plausible drug-targetable candidate genes for KRAS G12A-, G12D-, and G12V-driven colorectal cancer.
Ohnami S; Maruyama K; Chen K; Takahashi Y; Hatakeyama K; Ohshima K; Shimoda Y; Sakai A; Kamada F; Nakatani S; Naruoka A; Ohnami S; Kusuhara M; Akiyama Y; Kagawa H; Shiomi A; Nagashima T; Urakami K; Yamaguchi K
Mol Cell Biochem; 2021 Sep; 476(9):3469-3482. PubMed ID: 33982211
[TBL] [Abstract][Full Text] [Related]
9. Binding between the junctional proteins afadin and PLEKHA7 and implication in the formation of adherens junction in epithelial cells.
Kurita S; Yamada T; Rikitsu E; Ikeda W; Takai Y
J Biol Chem; 2013 Oct; 288(41):29356-68. PubMed ID: 23990464
[TBL] [Abstract][Full Text] [Related]
10. PLEKHA7: Cytoskeletal adaptor protein at center stage in junctional organization and signaling.
Shah J; Guerrera D; Vasileva E; Sluysmans S; Bertels E; Citi S
Int J Biochem Cell Biol; 2016 Jun; 75():112-6. PubMed ID: 27072621
[TBL] [Abstract][Full Text] [Related]
11. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
[TBL] [Abstract][Full Text] [Related]
12. Targeting antioxidant enzymes enhances the therapeutic efficacy of the BCL-X
Oh Y; Jung HR; Min S; Kang J; Jang D; Shin S; Kim J; Lee SE; Sung CO; Lee WS; Lee C; Jeong EM; Cho SY
Cancer Lett; 2021 Jan; 497():123-136. PubMed ID: 33068701
[TBL] [Abstract][Full Text] [Related]
13. Baseline MAPK signaling activity confers intrinsic radioresistance to KRAS-mutant colorectal carcinoma cells by rapid upregulation of heterogeneous nuclear ribonucleoprotein K (hnRNP K).
Eder S; Arndt A; Lamkowski A; Daskalaki W; Rump A; Priller M; Genze F; Wardelmann E; Port M; Steinestel K
Cancer Lett; 2017 Jan; 385():160-167. PubMed ID: 27793696
[TBL] [Abstract][Full Text] [Related]
14. Genome-Wide CRISPR Screen for Essential Cell Growth Mediators in Mutant KRAS Colorectal Cancers.
Yau EH; Kummetha IR; Lichinchi G; Tang R; Zhang Y; Rana TM
Cancer Res; 2017 Nov; 77(22):6330-6339. PubMed ID: 28954733
[TBL] [Abstract][Full Text] [Related]
15. Dual role of sprouty2 as an inhibitor of RAS/ERK-driven proliferation and a promoter of cancer invasion in KRAS wild-type colorectal cancer.
Lee CT; Chu CA; Wang YM; Wang YW; Chen YL; Ho CL; Yeh YM; Lin PC; Lin BW; Chen PC; Chen SH; Chan RH; Chang C; Chow NH
Mol Carcinog; 2023 Jul; 62(7):951-962. PubMed ID: 37014154
[TBL] [Abstract][Full Text] [Related]
16. PLEKHA7 is an adherens junction protein with a tissue distribution and subcellular localization distinct from ZO-1 and E-cadherin.
Pulimeno P; Bauer C; Stutz J; Citi S
PLoS One; 2010 Aug; 5(8):e12207. PubMed ID: 20808826
[TBL] [Abstract][Full Text] [Related]
17. PTPN2 regulates the activation of KRAS and plays a critical role in proliferation and survival of KRAS-driven cancer cells.
Huang Z; Liu M; Li D; Tan Y; Zhang R; Xia Z; Wang P; Jiao B; Liu P; Ren R
J Biol Chem; 2020 Dec; 295(52):18343-18354. PubMed ID: 33122197
[No Abstract] [Full Text] [Related]
18. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.
Wong CC; Xu J; Bian X; Wu JL; Kang W; Qian Y; Li W; Chen H; Gou H; Liu D; Yat Luk ST; Zhou Q; Ji F; Chan LS; Shirasawa S; Sung JJ; Yu J
Gastroenterology; 2020 Dec; 159(6):2163-2180.e6. PubMed ID: 32814111
[TBL] [Abstract][Full Text] [Related]
19. KRAS Mutation-Responsive miR-139-5p inhibits Colorectal Cancer Progression and is repressed by Wnt Signaling.
Du F; Cao T; Xie H; Li T; Sun L; Liu H; Guo H; Wang X; Liu Q; Kim T; Franklin JL; Graves-Deal R; Han W; Tian Z; Ge M; Nie Y; Fan D; Coffey RJ; Lu Y; Zhao X
Theranostics; 2020; 10(16):7335-7350. PubMed ID: 32641995
[No Abstract] [Full Text] [Related]
20. ARID1A facilitates KRAS signaling-regulated enhancer activity in an AP1-dependent manner in colorectal cancer cells.
Sen M; Wang X; Hamdan FH; Rapp J; Eggert J; Kosinsky RL; Wegwitz F; Kutschat AP; Younesi FS; Gaedcke J; Grade M; Hessmann E; Papantonis A; Strӧbel P; Johnsen SA
Clin Epigenetics; 2019 Jun; 11(1):92. PubMed ID: 31217031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
